Development · 26 Aug 2026

Aurigene Pharmaceutical Services entered into a long-term Manufacturing and Supply Agreement with a leading global pharmaceutical company for commercial drug-product manufacturing and supply of a diversified portfolio for USA, Europe, Canada and Emerging markets.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

thehindubusinessline.com25 Aug 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Dr. Reddy's Laboratories

₹1,206.20

▼ -2.17%

Close (EOD), as of 1 Oct 2026 · source

Dr. Reddy's Laboratories: results, dividends, orders, the full cited record →

More on Dr. Reddy's Laboratories

Barring Dr Reddy's Labs and Infosys, all Nifty 50 stocks succumbed to selling pressure as the market entered the last 60 minutes of trade.

29 Sep 2026 · 1 publisher

Dr Reddys Laboratories Ltd is quoting at Rs 1213, up 0.17% on the day as on 12:44 IST on the NSE.

24 Sep 2026 · 2 publishers

Dr Reddys Laboratories Ltd gained for a fifth straight session on September 23, 2026.

23 Sep 2026 · 1 publisher

Takeda's QDENGA is expected to become available in India in the first half of 2027, following an exclusive partnership with Dr Reddy’s Laboratories for its promotion and distribution in the private market.

19 Sep 2026 · 7 publishers

Dr. Reddy's Laboratories and Takeda Biopharmaceuticals India have entered into a distribution agreement under which Dr. Reddy's will promote and distribute Takeda's dengue vaccine, QDENGA®, across India's private market for pediatric and adult vaccination.

19 Sep 2026 · 3 publishers

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.